Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow

Favrot, M.; Frappaz, Didier; O, Maritaz; Philip, I; B, Fontanière; Gentilhomme, O; Bailly, Christiane; Zucker, J. M.; Gentet, Jean Claude; Kemshead, J T; Philip, Thierry

doi:10.1038/bjc.1986.220

Cited by 58 publications

(30 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several reports have demonstrated the high sensitivity (1 tumour cell in 10 4 to 10 6 normal cells) of immunocytological assays in BM (Cheung et al, 1986;Favrot et al, 1986;Gussetis et al, 1989), BM autograft (Combaret et al, 1989) and PB samples (Faulkner et al, 1998). Swerts et al (2004) compared IC applying only one anti-G D2 antibody to FC involving five differently labelled antibodies against G D2 , CD9, CD81 and CD56 on tumour cells and against CD45 on haematopoietic cells and concluded that the sensitivity of the flow cytometric assay was about 10 times lower if equal amounts of cells were analysed.…”

Section: Sensitivity Of Single-cell-based Assaysmentioning

confidence: 99%

See 1 more Smart Citation

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

et al. 2009

View full text Add to dashboard Cite

Disseminating disease is a predictive and prognostic indicator of poor outcome in children with neuroblastoma. Its accurate and sensitive assessment can facilitate optimal treatment decisions. The International Neuroblastoma Risk Group (INRG) Task Force has defined standardised methods for the determination of minimal disease (MD) by immunocytology (IC) and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) using disialoganglioside G D2 and tyrosine hydroxylase mRNA respectively. The INRG standard operating procedures (SOPs) define methods for collecting, processing and evaluating bone marrow (BM), peripheral blood (PB) and peripheral blood stem cell harvest by IC and QRT-PCR. Sampling PB and BM is recommended at diagnosis, before and after myeloablative therapy and at the end of treatment. Peripheral blood stem cell products should be analysed at the time of harvest. Performing MD detection according to INRG SOPs will enable laboratories throughout the world to compare their results and thus facilitate quality-controlled multi-centre prospective trials to assess the clinical significance of MD and minimal residual disease in heterogeneous patient groups.

show abstract

Section: Sensitivity Of Single-cell-based Assaysmentioning

confidence: 99%

“…The specific binding of antibodies to NB cells on cytospins or smears has been visualised by either cytochemical (Beck et al, 1988) or fluorescent (Favrot et al, 1986) detection method.…”

Section: Immunocytologymentioning

confidence: 99%

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

et al. 2009

View full text Add to dashboard Cite

show abstract

“…7 , While the latter approach has produced encouraging results in patients who have achieved complete remission (CR) or good partial remission (GPR), 7 ' 8 the problem of achieving such remission remains an obstacle. Although high overall response rates have been reported using a variety of multiagent regimens,' 1 -these are rarely durable and the stringency of restaging procedures-for example, the number of bone marrow aspirates and biopsies or use of bone scans-tends to vary from one report to another 9 , 10 and makes at least the so-called CR questionable. phase II pilot studies conducted by our group revealed an impressive response rate to a dose of 200 mg/m 2 CDDP in children with relapsed disease who had been previously treated with multiple drug schemata, including CDDP 60 to 100 mg/m2.'…”

mentioning

confidence: 99%

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.

Philip¹,

Ghalie²,

Pinkerton³

et al. 1987

JCO

Self Cite

View full text Add to dashboard Cite

Forty-seven children or adolescents with initial stage IV (42 patients) or stage III (five) advanced neuroblastoma (12 were progressing after relapse and 35 had never reached complete remission [CR] after conventional therapy) were included in a phase II study of the combination of high-dose VP-16 (100 mg/m 2 /d x 5) and high-dose cisplatin (CDDP) (40 mg/m 2 /d x 5). Twenty patients had received prior CDDP therapy (total dose, 100 to 640 mg/m2; median, 320 mg/m 2 ) and 38 of 47 had bone marrow involvement when included in the study. The overall response rate was 55%, with 22% CR. Duration of response was 5 to 18 months, with a median of 10 months. Eight patients are still disease free, with a median observation time of 13 months, but all had received additional therapy after two courses of this regimen. Gastrointestinal toxicity was frequent but tolerable. Myelosuppression was severe but of brief duration, ie, nadir of neutro-STAGE IV neuroblastoma in children over 1 year of age remains one of the major therapeutic challenges in pediatric oncology. Despite advances in conventional regimens 1 -6 and the recent introduction of high-dose chemoradiotherapy with bone marrow rescue, the long-term outcome remains disappointing.' 7 , While the latter approach has produced encouraging results in patients who have achieved complete remission (CR) phase II pilot studies conducted by our group revealed an impressive response rate to a dose of 200 mg/m 2 CDDP in children with relapsed disease who had been previously treated with multiple drug schemata, including CDDP 60 to 100 mg/m2.' 3 VM-26 was shown to be an active agent in phase II studies and although similar data with etoposide (VP-16) are limited, this agent actually shows a comparable activity.14-17 Its value has been shown when combined with low-dose CDDP.' 4 The main advantage over VM-26 is its better tolerance; allergic reactions to VM-26 occur in a high percentage of children with neuroblastoma. 4 The combination of VP-16 and

show abstract

“…4 In six of these patients this antibody positivity correlated with subsequent relapse despite treatment: in the remaining four insufficient follow up information was available for assessment. If in the absence of evidence of marrow infiltration by conventional examination of marrow aspirate and marrow biopsy specimen antibody positivity is to be accepted as evidence in its own right of marrow infiltration, the antibody must show a high specificity for neuroblastoma cells.…”

Section: Discussionmentioning

confidence: 99%

Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma.

Rogers¹,

Treleaven²,

Kemshead³

et al. 1989

J Clin Pathol

View full text Add to dashboard Cite

SUMMARY One hundred and sixty six bone marrow aspirates from children with abdominal neuroblastoma were independently examined for the presence of neuroblastoma cells by conventional haematological staining techniques and by indirect immunofluorescence using one or more of five monoclonal antibodies. Results using the two methods were evaluated by comparison with the results of bone marrow, bone and lymph node biopsy specimens taken at the same time, and in the light of the child's clinical course. One antibody, UJ13A, was found to have 98&5% specificity and 85-7% sensitivity, compared with sensitivities for conventional staining of 50% for aspirate alone and of aspirate or trephine biopsy specimen of 71 4%. The remaining antibodies UJ 127/11, UJ223/8, UJ181/4 and UJ167/1 1, with specificities in the range 94-99%, were found to have sensitivities in the range 47-61%, lower than the sensitivity of conventionally stained aspirate or trephine biopsy specimen. Routine immunofluorescence staining with monoclonal antibody UJ1 3A should increase the sensitivity of detection of metastatic neuroblastoma.

show abstract

Histological, cytological and immunological analyses are complementary for the detection of neuroblastoma cells in bone marrow

Cited by 58 publications

References 8 publications

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

A phase II study of high-dose cisplatin and VP-16 in neuroblastoma: a report from the Société Française d'Oncologie Pédiatrique.

Monoclonal antibodies for detecting bone marrow invasion by neuroblastoma.

Contact Info

Product

Resources

About